Join The Mandarin as we consider what the system design implications of immuno-oncology treatments are for policy makers and how regulators and payers around the world are adapting to this challenge across a variety of health care domains.
The new wave of immuno-oncology treatments for cancer is characterised by medicines that have multiple indications.
This paradigm shift from medicines that treat specific tumours to those that act on the immune system is causing all system managers to consider how to transition to this new world of multi-indication medicines.
Access to medicines with multiple indications may create some additional challenges compared to single indication products. For example, the approach adopted in many countries is for each new indication to be assessed, and for this to feed into a pricing and reimbursement (P&R) process. This means that every indication will require a separate process as if it was a new medicine – sometimes taking in excess of two years before patients can access them.
Medicines with multiple indications also introduce budget uncertainties and difficulties for payers. In the current system, payers often have no way of knowing when and how many indications will launch. This could have implications in terms of unexpected impact on spending. Where launches happen earlier, this clearly leads to increased need for resources, while delayed clinical trial results mean that less resources are being used.
Lastly, the whole reimbursement process around the assessment of immuno-oncology treatments for rare cancers with only a small population, challenges a review process that seeks to deliver the broadest health outcome for the best resource use.
Many countries are facing similar challenges. Several northern European countries now well advanced in the redesign of their systems to ensure their communities are able to benefit from the huge innovation and advances in health care and well being.
Join our experts as we consider how government adapts to this new world of multi-indication medicines and what changes in the system design and operation are needed to usher in this new era of immuno-oncology therapies.
Please note that this seminar is for public sector executives and managers only. If you are unable to attend and believe a senior agency colleague could benefit, please send your request through to Nicklas Wikblad at: [email protected]
A light lunch will be served during the seminar. There is no charge to attend, but seats are limited so RSVPs are essential. In order to attend the seminar, please RSVP below.
This seminar is brought to you by MSD.
Dr Deme Karikios, medical oncologist
Deme is the director of clinical trials at Nepean Cancer Care Centre in Sydney. He has research interests in costs and value of anticancer drugs, and decisions about treatment with expensive unsubsidised anticancer drugs. He recently submitted his PhD entitled “The consequences of rising anticancer drug costs in Australia.”
Sharon Winton, CEO of Lymphoma Australia
Sharon is a member of the Lymphoma Coalition and has been a health consumer representative on a number of stakeholder meetings including PBAC, biosimilars and access to medicines in Australia. Prior to her current role, Sharon worked with a private health insurance company in relationship and strategic management.
Megan Bohensky, head of market access, MSD Australia
A highly effective market access professional/health economist with experience in health services and pharmaceutical industries.
RSVP today – places filling fast